Hansen Medical to Exhibit Magellan(TM) Robotic System at 25th Annual
International Symposium on Endovascular Therapy
MOUNTAIN VIEW, CA -- (Marketwire) -- 01/15/13 -- Hansen Medical,
Inc. (NASDAQ: HNSN), a global leader in intravascular robotics, today
announced it will exhibit its Magellan(TM) Robotic System at the 25th
Annual International Symposium on Endovascular Therapy (ISET), from
January 19-23 at the Fontainebleau Miami Beach Hotel in Miami, FL.
The Company will be exhibiting the Magellan Robotic System at Booth
Additionally, Dr. Barry Katzen, founder and Medical Director of
Baptist Cardiac & Vascular Institute (Baptist Hospital of Miami), and
a course director at ISET, is scheduled to feature the Magellan
System in live cases at the conference.
"We are pleased that our Magellan Robotic System will be highlighted
at ISET, which is in its 25th year of bringing together
interventional cardiologists, vascular surgeons and other healthcare
professionals to focus on acquiring the latest knowledge and product
information related to interventional medicine and vascular disease,"
said Bruce Barclay, president and CEO of Hansen Medical. "The live
cases scheduled to be performed by Dr. Katzen will provide additional
opportunities for clinicians to view the significant clinical
benefits provided by the Magellan System. We continue to have growing
pipeline of commercial interest in our technology and look forward to
further building on this momentum at ISET."
About the Magellan(TM) Robotic System
Hansen Medical's Magellan
Robotic System is based upon the flexible robotic technology
incorporated in the Sensei X(R) Robotic Catheter System currently
sold in the U.S. and Europe, which has been used in nearly 10,000
patients, but includes a number of key enhancements. In particular,
the Magellan Robotic System:
-- Provides solid catheter stability for placement of therapeutic
-- Is designed to enable predictable procedure times and increased case
-- Allows for independent, individual robotic control of the distal tips
of both the outer sheath and the inner leader catheter, as well as
robotic manipulation of standard guidewires.
-- Is designed to allow for sufficient extension inside the body to
access hard to reach peripheral anatomy.
-- Preserves the open architecture featured in the Sensei System to allow
for the subsequent use of many 6F therapeutic devices on the market
-- Is designed to potentially reduce physician radiation exposure and
fatigue by employing a remote physician workstation.
About Hansen Medical, Inc.
Hansen Medical, Inc., based in Mountain
View, California, is the global leader in intravascular robotics,
developing products and technology designed to enable the accurate
positioning, manipulation and control of catheters and catheter-based
technologies. The Company's Magellan(TM) Robotic System, Magellan
Robotic Catheter and related accessories, which are intended to
facilitate navigation to anatomical targets in the peripheral
vasculature and subsequently provide a conduit for manual placement
of therapeutic devices, have undergone both CE marking and 510(k)
clearance and are commercially available in the European Union, and
the U.S. In the European Union, the Company's Sensei(R) X Robotic
Catheter System and Artisan Control Catheter are cleared for use
during electrophysiology (EP) procedures, such as guiding catheters
in the treatment of atrial fibrillation (AF), and the Lynx(R) Robotic
Ablation Catheter is cleared for the treatment of AF. This robotic
catheter system is compatible with fluoroscopy, ultrasound, 3D
surface map and patient electrocardiogram data. In the U.S. the
Company's Sensei X Robotic Catheter System and Artisan Control
Catheter were cleared by the U.S. Food and Drug Administration for
manipulation and control of certain mapping catheters in EP
procedures. In the United States, the Sensei System is not approved
for use in guiding ablation procedures; this use remains
experimental. The U.S. product labeling therefore provides that the
safety and effectiveness of the Sensei X System and Artisan Control
Catheter for use with cardiac ablation catheters in the treatment of
cardiac arrhythmias, including AF, have not been established.
Additional information can be found at www.hansenmedical.com.
This press release contains
forward-looking statements regarding, among other things, statements
relating to goals, plans, objectives, milestones and future events.
All statements, other than statements of historical fact, are
statements that could be deemed forward-looking statements, including
statements containing the words "plan," "expects," "potential,"
"believes," "goal," "estimate," "anticipates," and similar words.
These statements are based on the current estimates and assumptions
of our management as of the date of this press release and are
subject to risks, uncertainties, changes in circumstances and other
factors that may cause actual results to differ materially from the
information expressed or implied by forward-looking statements made
in this press release. Examples of such statements include statements
about the potential benefits of our technology and the value of our
intellectual property portfolio. Important factors that could cause
actual results to differ materially from those indicated by such
forward-looking statements include, among others: engineering,
regulatory, manufacturing, sales and customer service challenges in
developing new products and entering new markets; potential safety
and regulatory issues that could slow or suspend our sales; the
effect of credit, financial and economic conditions on capital
spending by our potential customers; the uncertain timelines for the
sales cycle for newly introduced products; the rate of adoption of
our systems and the rate of use of our catheters; the scope and
validity of intellectual property rights applicable to our products;
competition from other companies; our ability to recruit and retain
key personnel; our ability to maintain our remedial actions over
previously reported material weaknesses in internal controls over
financial reporting; our ability to manage expenses and cash flow,
and obtain additional financing; and other risks more fully described
in the "Risk Factors" section of our Quarterly Report on Form 10-Q
for the quarter ended September 30, 2012 filed with the SEC on
November 9, 2012 and the risks discussed in our other reports filed
with the SEC. Given these uncertainties, you should not place undue
reliance on the forward-looking statements in this press release. We
undertake no obligation to revise or update information herein to
reflect events or circumstances in the future, even if new
information becomes available.
Hansen Medical, Heart Design (Logo), Hansen Medical (with Heart
Design), Sensei and Lynx are registered trademarks, and Magellan and
NorthStar are trademarks of Hansen Medical, Inc. in the United States
and other countries.
Peter J. Mariani
Chief Financial Officer
Hansen Medical, Inc.
FTI Consulting, Inc.
Press spacebar to pause and continue. Press esc to stop.